NCT04098263View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

April 15, 2020

Study Completion Date

June 24, 2020

Conditions
Campylobacter Jejuni Infection
Interventions
BIOLOGICAL

LMN-101

variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass

Trial Locations (1)

4029

Royal Brisbane & Women's Hospital, Herston

Sponsors
All Listed Sponsors
lead

Lumen Bioscience, Inc.

INDUSTRY